Versantis announces Dr Robert Schier to its Board along with raising CHF16m Series B financing led by Swisscanto Invest

– SWITZERLAND, Zurich –  Versantis, a clinical-stage biotech company developing disruptive therapies for rare liver and pediatric diseases, today announces the successful completion of an oversubscribed CHF 16 million Series B financing round led by Swisscanto Invest joined by Esperante Ventures and investiere, as well as new private investors. Existing investors Redalpine HealthEquity, and Zürcher Kantonalbank Start-up Finance also participated in this round.

With the closing of this financing round, Dr Robert Schier, Investment Director PE/VC Health-Tech at Swisscanto Invest, will join Versantis’ Board of Directors, chaired by Peter Nicklin, a senior healthcare executive and entrepreneur.

Earlier in the year, Versantis started a first-in-human clinical trial with VS-01, a multi-organ supporting therapy for liver cirrhosis. The proceeds from this new financing will be mainly used to assess the safety of VS-01 after multiple doses and establish its clinical proof of concept in the decompensated liver cirrhosis indication as well as in the rare Acute-on-Chronic Liver Failure (ACLF) patient population.

“Since the launch of Versantis, we have matured and successfully translated our unique technology into a potentially lifesaving therapy, now being evaluated in cirrhotic patients. This financing is yet another validation of the important work accomplished by the whole Versantis team,” said Dr. Vincent Forster, CEO and co-founder of Versantis.

“We are thrilled to receive the support and partnership from this group of top-tier life science investors to help us achieve our mission. With this funding, we aim to demonstrate VS-01 clinical benefit and position Versantis as a key pioneer in the care of serious liver diseases,” he added.

Dr. Meriam Kabbaj, COO and co-founder of Versantis commented: “The Series B closing coincides with the regulatory clearance and initiation of Versantis’ first in human study, one of the most important milestones the company has achieved so far, in order to assess the safety of VS-01 in cirrhotic patients with ascites and mild hepatic encephalopathy. This funding is pivotal to support clinical development towards proof of efficacy in two indications of high unmet medical need. It highlights our commitment to soon transform the lives of patients with liver disease and their families.”

“We are excited to join Versantis as a lead investor on its journey to develop and launch a novel therapy, which could have a significant impact for a growing number of patients with liver diseases. Swisscanto Invest is convinced about the unique clinical approach, the rigorous planning and execution of the project and the key stakeholders of the company as an excellent basis of success,” stated Dr. Schier.

“The company has good momentum and the therapy fills a big and underserved medical need,” added Dr. Sidler, Redalpine.

About Versantis

Versantis is a clinical-stage biotech company focused on the development of orphan drugs in liver diseases and pediatric inborn errors of metabolism. Founded by leading scientists from ETH Zurich and industry experts, Versantis is pursuing innovative therapies for the acute care of serious liver conditions based on its proprietary liposomes-based detoxification platform technology. Its lead candidate, VS-01, uses a disruptive route to enhance the clearance of ammonia and other toxins from the body. The company’s mission is to bring therapeutic solutions to many patients in need by timely supporting acute decompensations of cirrhosis (Versantis’ most advanced program) as well as rare hyperammonemic genetic disorders in children. VS-01 is currently being evaluated in first-in-human clinical trials, with outcomes expected mid-2020. VS-01 was granted orphan drug designations in acute liver failure by the EMA and in ACLF by the FDA, which will streamline its clinical development pathway.

For more information, visit: www.versantis.ch

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.